Please login to the form below

Not currently logged in


This page shows the latest HBV news and features for those working in and with pharma, biotech and healthcare.

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Precision is pleased that initial studies with our ARCUS platform have established an important role for genome editing in their HBV program. ... We look forward to exploring this [Precision BioScience’s genome editing] technology as an important

Latest news

  • Gilead's Hepatitis B therapy Vemlidy granted EU approval Gilead's Hepatitis B therapy Vemlidy granted EU approval

    The European Commission has granted Gilead's Vemlidy European marketing authorisation, making it the first new hepatitis B virus (HBV) treatment to receive EU approval in nearly a decade. ... In Europe, a WHO report from 2016 showed that 13 million

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk. Gilead Sciences' once-daily chronic hepatitis B virus (HBV) therapy Vemlidy has been recommended for the treatment of adults and adolescents ... The CHMP's recommendation follows the

  • J&J buys firm seeking hepatitis B cure J&J buys firm seeking hepatitis B cure

    Acquires Philadelphia-based Novira therapeutics. Johnson &Johnson (J&J) has agreed to buy a Pennsylvania biotech company that is trying to develop treatments to cure hepatitis B virus (HBV) infection. ... and disrupts the HBV lifecycle by inducing the

  • Novartis meningitis vaccine performs well

    The vaccine was administered at 2, 4, 6 and 12 months, both alone and in combination with other paediatric vaccines (DTaP, IPV, HBV, Hib, pneumococcal). .

  • GSK and Gilead take HBV drug Viread to Asia

    The deal also gave GSK the right to, under certain circumstances, commercialise tenofovir for the treatment of HBV. ... Viread is currently approved as an HBV treatment in Australia, Canada, European Union, New Zealand, Turkey and the US.

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Product / Technology. Deal Type. Headline. ($). Arrowhead/. Janssen (J&J). Development &commercialisation of ARO‐HBV, based on. ... the TRiM platform, for chronic HBV infection. Licence. $3.7B. Endocyte /. Novartis. Radiopharmaceuticals and drug

  • Pharma deals in April 2015 Pharma deals in April 2015

    These are key markets for this product as more than 75% of all HCC cases occur in the APAC region, largely in association with chronic hepatitis B virus (HBV) infection.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...